MSFrontier

Study Evaluating Mitoxantrone in Multiple Sclerosis

A Double-Blind, Three-Armed, Randomized Phase-III-Study, to Compare the Efficacy, Tolerability and Safety of Three Doses of Mitoxantrone in the Treatment of Patients With Secondary Progressive Multiple Sclerosis
Stopped earlyPhase 3Progressive MSNCT00146159

What it found

Stopped early

The trial ended early for another reason (see below).

This trial finished 19 years ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

  • Mitoxantrone

What it measured

Main measures

  • 3 clinical measures combined in a multivariate analysis: confirmed Expanded Disability Status Scale(EDSS)

    3 years

    Disability progression

  • deterioration, change of ambulation index, time to first relapse requiring corticoid treatment

    3 years

    Relapses

Other measures (1)

  • derivations of EDSS and relapses; MRI (baseline, 2 years)

    3 years

    Disability progressionRelapsesMRI lesions

Who could take part

Progressive MS · 18 to 55

Inclusion Criteria: * Secondary progressive MS in an active stage * EDSS between 3 and 6 Exclusion Criteria: * Benign or primary progressive MS * Patients with cardiac risk factors * Patients who have already received mitoxantrone

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of mitoxantrone in these patients.

Papers

    Loading reviews and guidelines…

    Related trials

    History

      1. Started

        Mar 2005

      2. Main results due

        Sept 2007

      Assembled by software from public sources and not checked by people. Each record links to its source. Report an error